Menu

Discredited Stem Cell Researcher Fired

The researcher who falsely claimed to treat human patients with their own stem cells is dismissed, but insists that he did perform the procedure on one patient.

Oct 23, 2012
Dan Cossins

Tokyo Medical and Dental University. Wikimedia Commons, Rs1421The University of Tokyo last week (October 19) dismissed Hisashi Moriguchi, the researcher who claimed to have treated human patients with their own induced pluripotent stem cells (iPSCs), ScienceInsider reported. The dismissal came after Moriguchi admitted at a press conference in New York (October 13) that his original claim—that he had injected cardiac muscle cells derived from iPSCs into the hearts of five patients and seen positive therapeutic effects—was false.

But Moriguchi maintains that the procedure was carried out on a single patient—not at Harvard General Hospital in February 2012, as he originally claimed, but last June at a Boston hospital he declined to name.

Moriguchi’s claims, presented at the New York Stem Cell Foundation meeting at Rockefeller University, New York, quickly raised suspicions. Alerted to the story by Nature, spokespersons for the Massachusetts General Hospital (MGH) and Harvard Medical School—listed as collaborating institutions on his papers—denied that the procedures had taken place there. Moriguchi was a visiting fellow at Harvard for just one month in late 2009, they said. Moreover, several scientists named as collaborators have distanced themselves from any of the clinical work claimed by Moriguchi.

Although he admitted making some “procedural” mistakes, Moriguchi expressed disappointment that scientists listed as co-authors on some of his papers have asked for their names to be removed. He always showed them final versions before submission, he told ScienceInsider. He also tried to clarify his affiliations, insisting that he was established in an ongoing position at MGH in 2006. A spokesperson for MGH denied this.

Then he explained that despite not having a solid background in molecular biology—he has a degree in nursing and a masters in health promotion—he had taught himself the experimental techniques. He said he rented a lab in Boston, where he worked with an unnamed collaborator to culture the 30 million cardiac muscle cells he insists were injected into a heart disease patient. The collaborator has since cut off contact, he said, “perhaps because of the publicity.”

Finally, Moriguchi said he could understand why his claims have been met with suspicion. “[It] is difficult to believe as it stands. That’s why I want to gather and present the evidence,” he told ScienceInsider. He also said he will cooperate with investigations.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.